SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Jenni Virtanen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsinki University Hospital fundings, Jane and Aatos Erkko foundation.
Abstract (Originalsprache)
We studied the development of the severe acute respiratory syndrome‐related coronavirus (SARS‐CoV‐2) pandemic in southern Finland in 2020 and evaluated the performance of two surrogate immunoassays for the detection of neutralizing antibodies (NAbs). The data set consisted of 12 000 retrospectively collected samples from pregnant women in their first trimester throughout 2020. All the samples were initially screened for immunoglobulin G (IgG) with SARS‐CoV‐2 spike antibody assay (EIM‐S1, Euroimmun) followed by confirmation with nucleocapsid antibody assay (Architect SARS‐CoV‐2, Abbott). Samples that were reactive (positive or borderline) with both assays were subjected to testing with commercial surrogate immunoassays of NeutraLISA (EIM) and cPass TM (GenScript Biotech Corporation) by using pseudoneutralization assay (PNAbA) as a golden standard. No seropositive cases were detected between January and March. Between April and December, IgG (EIM‐S1 and Abbott positive) and NAb (PNAbA positive) seroprevalences were between 0.4% and 1.4%. NeutraLISA showed 90% and cPass 55% concordant results with PNAbA among PNAbA negative samples and 49% and 92% among PNAbA positive samples giving NeutraLISA better specificity but lower sensitivity than cPass. To conclude, seroprevalence in pregnant women reflected that of the general population but the variability of the performance of serological protocols needs to be taken into account in inter‐study comparison.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
- Department of Virology, University of Helsinki, Helsinki, Finland.
- HUS Diagnostic Center, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Jenni Virtanen, Essi M Korhonen, Anne J Jääskeläinen
Förderung
- Helsinki University Hospital fundings
- Jane and Aatos Erkko foundation
Zitieren
APA
Virtanen, J., Korhonen, E. M., Salonen, S., Vapalahti, O., Sironen, T., & Jääskeläinen, A. J. (2024). SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays. Journal of Medical Virology. https://doi.org/10.1002/jmv.29415
Vancouver
Virtanen J, Korhonen EM, Salonen S, Vapalahti O, Sironen T, Jääskeläinen AJ. SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays. Journal of Medical Virology. 2024. doi:10.1002/jmv.29415
BibTeX
@article{Virtanen2024,
author = {Virtanen, Jenni and Korhonen, Essi M and Salonen, Sami and Vapalahti, Olli and Sironen, Tarja and Jääskeläinen, Anne J},
title = {SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29415}
}
EUVIMED